Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon Sussman

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
The Journal of Allergy and Clinical Immunology. in Practice|March 1, 2025
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)Jacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 1, 2021
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial ResultsJacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2020
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year resultsDavid M Fleischer, Wayne G Shreffler, Dianne E Campbell, et al.
Allergy|September 18, 2021
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticariaTorsten Zuberbier, Amir Hamzah Abdul Latiff, Mohamed Abuzakouk, et al.
The New England Journal of Medicine|November 20, 2018
AR101 Oral Immunotherapy for Peanut Allergy, Brian P Vickery, Andrea Vereda, et al.
Clinical and Translational Allergy|September 25, 2023
A concept for integrated care pathways for atopic dermatitis-A GA<sup>2</sup> LEN ADCARE initiativeTorsten Zuberbier, Amir Abdul Latiff, Xenofon Aggelidis, et al.
Allergy|April 6, 2020
Definition, aims, and implementation of GA<sup>2</sup> LEN/HAEi Angioedema Centers of Reference and ExcellenceMarcus Maurer, Werner Aberer, Rosana Agondi, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
The Journal of Allergy and Clinical Immunology. in Practice|March 1, 2025
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)Jacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 1, 2021
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial ResultsJacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2020
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year resultsDavid M Fleischer, Wayne G Shreffler, Dianne E Campbell, et al.
Allergy|September 18, 2021
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticariaTorsten Zuberbier, Amir Hamzah Abdul Latiff, Mohamed Abuzakouk, et al.
The New England Journal of Medicine|November 20, 2018
AR101 Oral Immunotherapy for Peanut Allergy, Brian P Vickery, Andrea Vereda, et al.
Clinical and Translational Allergy|September 25, 2023
A concept for integrated care pathways for atopic dermatitis-A GA<sup>2</sup> LEN ADCARE initiativeTorsten Zuberbier, Amir Abdul Latiff, Xenofon Aggelidis, et al.
Allergy|April 6, 2020
Definition, aims, and implementation of GA<sup>2</sup> LEN/HAEi Angioedema Centers of Reference and ExcellenceMarcus Maurer, Werner Aberer, Rosana Agondi, et al.
Pageof 7